Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity

Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity

Abstract Introduction Advanced non-small cell lung cancer (NSCLC) is still a therapeutic challenge as the 5-year survival is under 30%. The optimal treatment regimen is still under debate. Hypothesis Neo adjuvant (NA) treatment given pre-pneumonectomy does not increase surgical complexity or peri-OP...

Full description

Bibliographic Details
Main Authors: Dan Aravot, Yaron D. Barac, Efrat Krutzwald-Josefson, Aaron M. Allen, Dov Flex, Nir Peled, Mordechai R. Kramer, Yuri Peysakhovich, Milton Saute
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Journal of Cardiothoracic Surgery
Subjects:
Pneumonectomy
Neo adjuvant therapy
Chemo-radiation
Online Access:http://link.springer.com/article/10.1186/s13019-018-0829-z

Internet

http://link.springer.com/article/10.1186/s13019-018-0829-z

Similar Items